Nuvalent, Inc. reported a net loss of $84.582 million for the three months ended March 31, 2025, an increase from the $44.482 million net loss in the same period last year. This was primarily driven by increased research and development expenses related to advancing product candidates and higher general and administrative costs.

Nuvalent reported its fourth quarter and full year 2024 financial results, highlighting pipeline advancements, the reiteration of key milestones, and the implementation of global Expanded Access Programs for zidesamtinib and neladalkib.

Nuvalent reported third quarter 2024 financial results, highlighting pipeline progress and reiterating key anticipated milestones. The company's cash position is strong at $1.2 billion, expected to extend operating runway into 2028.

Nuvalent reported its Q2 2024 financial results, highlighting strong execution across its pipeline, including the initiation of the Phase 2 portion of the ALKOVE-1 trial for NVL-655, receipt of FDA breakthrough therapy designation for both zidesamtinib and NVL-655, and initiation of the HEROEX-1 trial for NVL-330. The company's cash, cash equivalents, and marketable securities are expected to support operating runway into 2027.

Nuvalent reported its Q1 2024 financial results, highlighting pipeline progress and reiterating key milestones. The company's cash position is strong, with an operating runway anticipated into 2027. Clinical updates from the ARROS-1 and ALKOVE-1 trials are expected in the second half of 2024, and the first patient in the HER2 program is expected to be dosed this year.

Nuvalent reported its Q4 and full year 2023 financial results, highlighting pipeline progress and reiterating key anticipated milestones. The company's cash position is expected to fund operations into 2027.

Nuvalent reported a net loss of $33.6 million for the third quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $413.3 million as of September 30, 2023, which, combined with the proceeds from a recent public offering, are expected to extend the operating runway into 2027.

Nuvalent reported its second quarter 2023 financial results, highlighting the progress of its pipeline, including ongoing clinical trials for NVL-520 and NVL-655, and the advancement of NVL-330 toward clinical development. The company's cash, cash equivalents, and marketable securities are expected to support operations into the second half of 2025.

Nuvalent reported its Q1 2023 financial results, with a net loss of $25.2 million, or $0.44 per share. The company's cash, cash equivalents, and marketable securities totaled $450.5 million as of March 31, 2023, expected to fund operations into the second half of 2025. Preliminary data from the ALKOVE-1 trial of NVL-655 is anticipated in the second half of 2023.

Nuvalent reported a strong financial position with $472.2 million in cash, cash equivalents and marketable securities, which is expected to fund operations into the second half of 2025. The company highlighted progress in its clinical trials for NVL-520 and NVL-655 and the nomination of NVL-330 as a third development candidate.

Nuvalent reported preliminary Phase 1 clinical data from ARROS-1 Study, enrollment progressing in ALKOVE-1 Phase 1/2 trial, and NVL-330 demonstrates potency and selectivity for HER2 Exon 20 insertion mutations. The company's cash, cash equivalents, and marketable securities are expected to extend the operating runway into the second half of 2025.

Nuvalent reported a net loss of $18.5 million for the second quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $257.0 million as of June 30, 2022, which is expected to fund operations into 2024. The company is advancing its pipeline with clinical trials ongoing for NVL-520 and NVL-655 and expects to select two additional development candidates in 2022.

Nuvalent reported a net loss of $17.5 million, or $0.36 per share, for the first quarter of 2022. The company ended the quarter with $272.7 million in cash, cash equivalents, and marketable securities.

Nuvalent reported a net loss of $17.3 million for the fourth quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $288.1 million as of December 31, 2021. The IND application for NVL-655 was cleared by the FDA, and enrollment is ongoing in the ARROS-1 trial of NVL-520.